| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |